Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve

Clin Transl Med. 2023 Sep;13(9):e1426. doi: 10.1002/ctm2.1426.

Qing Zhou^{1

2

3}, Jingnan Yuan^{1

2

3}, Kui Wu^{1

2

3}, Jun Yin^{4

5}, Lijie Tan^{4

5}

¹ Guangdong Provincial Key Laboratory of Human Disease Genomics, Shenzhen Key Laboratory of Genomics, BGI Research, Shenzhen, China.
² HIM-BGI Joint Lab, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, BGI Research, Hangzhou, China.
³ Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
⁴ Department of Thoracic Surgery, Cancer Center, Zhongshan Hospital of Fudan University, Shanghai, China.
⁵ Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China.

No abstract available

Keywords: biomarkers; locally advanced oesophagal squamous cell carcinoma; neoadjuvant immunotherapy.

Publication types